Skip to main content

Anti-inflammatory drug may cut lung cancer risk, Indian doctors positive



With researchers finding in a trial involving 10,000 adults that an existing anti-inflammatory drug has the potential to lower lung cancer risk, doctors in India have expressed hope for better tackling of the critical disease.

According to a study published in the journal Lancet, death from cancer was reduced by half in a group of people who received the highest dosage of the drug known as Canakinumab and also led to 67 per cent reduction in lung cancer incidence.

Canakinumab was found to lower inflammation, without affecting cholesterol level — which was the widely used approach for many years. It was also found effective against heart attack, stroke and cardiovascular death.

"As a rule, anti-inflammatory drugs have a role in prevention of cancer. With the rise in pollution levels across the country, there will be added burden on the lungs of those who may be suffering for lung cancer," Dinesh Katiyar, Senior Consultant (Surgical Oncologist) at Venkateshwar Hospital here, told IANS.

"Any drug that can prevent lung cancer in India will definitely be welcome," Katiyar added.
The drug marketed by drug major Novartis as Ilaris was earlier designed for treating gout and rheumatoid arthritis — which has high inflammatory markers similar to those seen in cancers and heart disease patients.

Hence, when investigated for the cancers and heart disease, those on the medium dose of Canakinumab had a 15 per cent lower chance of another heart attack, a stroke or a heart-related death over the next four years.

Lung cancer rates were reduced 26 per cent, 39 per cent and 67 per cent for the low, medium and high doses of Canakinumab, respectively.

ᐧ

Comments

Post a Comment

Popular posts from this blog

Registration of herbal trials in CTRI is not mandatory

A trial patient visited the site complaining breathlessness and tachycardia. The investigator advised hospitalization but as subject could not afford the expenses, he refused for admission. Is this an SAE because investigator advised hospitalization? G Praveen Kumar. If the patient was not hospitalized, it does not fall into SAE criteria of hospitalization. However, it appears from your mail that the PI felt that the event was serious enough to admit the subject for treatment. This makes it an “important medical event." As per ICH E2A such event also are considered serious. See the ICH E2A excerpt below: Medical and scientific judgement should be exercised in deciding whether expedited reporting is appropriate in other situations, such as important medical events that may not be immediately life-threatening or result in death or hospitalisation but may jeopardise the patient or may require intervention to prevent one of the other outcomes listed in the defin...
Post a Comment
Read more

Unani medicine research institute to come up in Faridabad

A national research institute of 'Unani' medicine will be set up at a village in Faridabad district, a spokesman of Haryana government said today. The institute, which will provide healthcare facilities in the field of non-communicable diseases, would also include a 120-bedded in-patient department, the spokesman of the Ayush department said. Chief Minister Manohar Lal Khattar has approved a proposal to allot land of Kheri Gujran village for the institute. The institute would be developed as a state-of-the-art research centre with facilities for pre-clinical studies, clinical trials, drug standardisation and cultivation of medicinal plants used in 'Unani' system, the spokesman said. It would also offer facilities such as research and geriatric OPDs, speciality clinics, he said. The institute would have laboratories for bio-chemistry, pathology, radiology and USG, drug standardisation, immunology, pharmacognocy and phytochemistry, besides regimental therapy unit, library...
Post a Comment
Read more

The polypill: Medicine's magic bullet

The capsule costs pennies, contains a simple cocktail of medicines, and halves the number of strokes and heart attacks. Doctors want to hand it out in the first mass medication for the middle-aged in Britain. So why are the big drug companies so uninterested? The magic bullet, containing five medicines in a single capsule, sharply reduced cholesterol and blood pressure levels and has the potential to "halve cardiovascular events in average middle-aged individuals", the researchers say. The finding is a major boost for a medication with huge potential against the worldwide epidemic of heart disease and stroke. Doctors say that, if further trials prove successful, all men aged over 50 and women aged over 60 should be offered the pill in what would be the first example of mass medication for the middle-aged in Britain. Yet no Western pharmaceutical company has shown interest in developing the so-called polypill because it does not promise big profits. It would sell for pennies b...
Post a Comment
Read more